Home » Authors » Kim Coghill

Articles by Kim Coghill

Santarus Gets FDA Approval For Rapinex Powder Version

June 17, 2004

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

June 17, 2004

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

Momentum Growing For Effort To Legalize Drug Importation

June 14, 2004

NCI, CMS Begin Initiative To Improve Information On Cancer

June 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.